Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population

Ophthalmology and Therapy

Volumn 4, Issue 1, 2015, Pages 1-19

  Sangwan, Virender S ^a   Pearson, P Andrew ^b   Paul, Hemanth ^c   Comstock, Timothy L ^c  

^a L V PRASAD EYE INSTITUTE   (India)

^b UNIVERSITY OF KENTUCKY   (United States)

^c BAUSCH AND LOMB   (United States)

Author keywords

Adjunctive therapy; Asian population; Fluocinolone acetonide intravitreal implant; Posterior uveitis; Randomized clinical trial; Retisert; Uveitis recurrence

Indexed keywords

FLUOCINOLONE ACETONIDE;

ADJUVANT THERAPY; ARTICLE; ASIAN; BLURRED VISIO; CAPSULE OPACIFICATION; CATARACT; CATARACT EXTRACTION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EVISCERATION; EYE PAI; FEMALE; GLAUCOMA; HUMAN; HYPOTONY MACULOPATHY; IMPLANT; IMPLANT PROTRUSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; NECROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; SCHOOL CHILD; SCLERAL MELT; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84944258545     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-014-0027-6     Document Type: Article

References (30)

1. Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159–62.
2. Forster DJ. General approach to the uveitis patient and treatment strategies. In: Yanoff M, Duker JS, editors. Ophthalmology. 2nd ed. St. Louis: Mosby; 2004. p. 1115–20.
3. Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011;16:309–22.
4. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218:223–36.
5. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs. 1995;49:213–23.
6. Foster SC. The Ocular Immunology and Uveitis Foundation. Available from http://www.uveitis.org/patients/education/ glossary/t-z#UVEITIS. Accessed March 18, 2014.
7. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6.
8. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1–13.
9. Becker MD, Smith JR, Max R, Fiehn C. Management of sight-threatening uveitis: new therapeutic options. Drugs. 2005;65:497–519.
10. Acharya N, Young L. Sustained-release drug implants for the treatment of intraocular disease. Int Ophthalmol Clin. 2004;44:33–9.
11. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–33.
12. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol. 2007;18:235–9.
13. Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal disease. Sci World J. 2014;2014:989501.
14. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altawheel MM, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis. The multicenter uveitis steroid treatment trials. Ophthalmology. 2011;118:1916–26.
15. Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. 2006;26(suppl):1–16.
16. Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother. 2007;41:449–54.
17. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trail of a fluocinolone acetonide implant to treated posterior uveitis. Ophthalmology. 2005;112:1192–8.
18. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: 3-year clinical trial results. Arch Ophthalmol. 2008;126:1191–201.
19. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–7.
20. Pavesio C, Sierhut M, Bairi K. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567–75.
21. Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;. doi:10.1016/j.ophtha.2014.07.007 [Epub ahead of print].
22. Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–9.
23. Sheppard JD, Nguyen QD, Usner DW, et al. Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant. Clin Ophthalmol. 2012;6:79–85.
24. Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol. 1997;41:361–94.
25. Ritch R. Pathophysiology of glaucoma in uveitis. Trans Ophthalmol Soc UK. 1981;101(Pt 3):321–4.
26. Herbert HM, Viswanathan A, Jackson H, Lightman SL. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma. 2004;13:96–9.
27. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15:439–50.
28. Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol. 2006;17:235–44.
29. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125:1478–85.
30. ® (fluocinolone acetonide intravitreal implant) 0.59 mg prescribing information. Rochester: Bausch & Lomb, Inc.; 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021737s019.pdf